January 19, 2023 12:42 PM EST
Pharma
Manufacturing

In­tas Phar­ma­ceu­ti­cals un­der FDA scruti­ny over 'cas­cade of fail­ure' in over­sight of GMP doc­u­ments

Nicole DeFeudis

Editor

In­tas Phar­ma­ceu­ti­cals is in the FDA’s hot seat af­ter in­spec­tors not­ed a va­ri­ety of is­sues on a re­cent plant vis­it, in­clud­ing shred­ded records that were …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

David Ep­stein gets $140M for Ot­ti­mo's bi­func­tion­al take on hot PD-1xVEGF field

Roche’s Parkin­son’s drug flunks sec­ond mid-stage tri­al

Sang­amo strikes an­oth­er brain-tar­get­ing AAV part­ner­ship, this time with Astel­las

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Ex­clu­sive: Col­or Health alums raise $10M for new start­up, us­ing AI for reg­u­la­to­ry work

A service from the Financial Times